Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
Mirum Pharmaceuticals (MIRM) Stock Price & Analysis
586 Followers
MIRM Stock Chart & Stats
Day’s Range$23.14 - $24.62
52-Week Range― - ―
Previous Close$24.02
Volume817.34K
Average Volume (3M)N/A
Market Cap
$1.14B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$48.17Price Target Upside96.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Mirum Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Future ProspectsWith positive Phase 3 RESTORE data, Mirum's bile acid products could support NDA filing and penetrate the cerebrotendinous xanthomatosis patient market.
Commercial Strategy And Market PositioningMaralixibat (Livmarli) is seen as a cornerstone of Mirum's commercial story, with its broad approval label likely positioning it well against competitors and potential for revenue growth.
Drug Approval And Market PotentialAnalyst recommends a Buy rating for Mirum Pharmaceuticals with a $48 target price, recognizing the FDA approvals for maralixibat in treating rare cholestatic conditions as significant validations of the drug's mechanism.
Bears Say
Drug Approval And SalesMaralixibat misses in the Phase 2b EMBARK trial for biliary atresia, potentially limiting future revenue streams.
Drug Efficacy And Market PotentialVolixibat falls short of expectations in the PBC treatment market due to competitive intensity, which may challenge future sales.
Financial ForecastAnalyst projects a 2024 net loss of $72.2M for a diluted EPS of ($1.52), indicating financial struggles ahead.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Currently, no data Available
What is Mirum Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is May 02, 2024 which is in 6 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Feb 28, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.39.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -$0.42.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Currently, no data Available
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went down -0.623%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Among the largest hedge funds holding Mirum Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds Mirum Pharmaceuticals Inc’s shares valued at 16M.
---
Mirum Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.17 (96.69% Upside)
$48.17 (96.69% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 209.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $441.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.04%
12-Months-Change
Fundamentals
Return on Equity
-82.37%
Trailing 12-Months
Asset Growth
83.23%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
---
MIRM Company Deck
---
MIRM Earnings Call
Q4 2024
0:00 / 0:00
---
MIRM Stock 12 Months Forecast
Average Price Target
$48.17
▲(96.69% Upside)
Technical Analysis
Amicus
―
Ultragenyx Pharmaceutical
―
Corbus Pharmaceuticals
―
Rhythm Pharmaceuticals
―
Best Analysts Covering MIRM
1 Year
1 Year Success Rate
18/28 ratings generated profit
1 Year Average Return
+16.84%
reiterated a buy rating 18 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +16.84% per trade.
---